Medtronic (NYSE: MDT) taps Dr. Kweli Thompson to lead neuroscience unit
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Medtronic plc reported a leadership change in its Neuroscience Portfolio. Brett Wall will depart his role as Executive Vice President and President, Neuroscience Portfolio, and remain with the company until September 1, 2026 to support an orderly transition. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will become Executive Vice President and President, Neuroscience Portfolio effective June 1, 2026. Mr. Wall will receive severance payments and benefits consistent with Medtronic’s standard executive officer severance practices described in its 2025 proxy statement.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
1.125% Notes 2027: 1.125% Senior Notes due 2027
3.000% Notes 2028: 3.000% Senior Notes due 2028
3.875% Notes 2036: 3.875% Senior Notes due 2036
+3 more
6 metrics
1.125% Notes 2027
1.125% Senior Notes due 2027
Listed on New York Stock Exchange as MDT/27
3.000% Notes 2028
3.000% Senior Notes due 2028
Listed on New York Stock Exchange as MDT/28A
3.875% Notes 2036
3.875% Senior Notes due 2036
Listed on New York Stock Exchange as MDT/36
4.150% Notes 2053
4.150% Senior Notes due 2053
Listed on New York Stock Exchange as MDT/53
Transition effective date
June 1, 2026
Dr. Thompson assumes Neuroscience Portfolio leadership
End of transition period
September 1, 2026
Brett Wall remains employed through this date
Key Terms
Emerging growth company, Executive Vice President, Neuroscience Portfolio, Cardiac Rhythm Management, +1 more
5 terms
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Executive Vice President financial
"Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio"
An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.
Neuroscience Portfolio other
"Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026"
Cardiac Rhythm Management other
"Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management"
Cardiac rhythm management is the set of medical devices and treatments used to monitor and correct abnormal heartbeats, such as pacemakers, implantable defibrillators, cardiac resynchronization systems, and related monitoring services. Investors care because this is a steady, technology-driven market with durable revenue from device sales, follow-up care, software updates and remote monitoring—similar to buying both a home thermostat and the ongoing service plan that keeps it running reliably.
severance payments and benefits financial
"Mr. Wall is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices"
FAQ
What executive leadership change did Medtronic (MDT) disclose in this 8-K?
Medtronic disclosed that Brett Wall will leave his role as Executive Vice President and President, Neuroscience Portfolio, and Dr. Kweli Thompson will assume that position effective June 1, 2026, providing continuity for the business.
When will Dr. Kweli Thompson take over Medtronic’s Neuroscience Portfolio?
Dr. Kweli Thompson will assume the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026. This scheduled date provides a defined handover period from outgoing leader Brett Wall.
How long will Brett Wall remain at Medtronic (MDT) after stepping down?
Brett Wall will remain an employee of Medtronic until September 1, 2026. During this period, he will assist with the leadership transition of the Neuroscience Portfolio to Dr. Kweli Thompson.
Will Brett Wall receive severance benefits from Medtronic (MDT)?
Yes, Brett Wall is entitled to severance payments and benefits. These will follow Medtronic’s standard severance practices for executive officers, as described in the company’s 2025 proxy statement filed with the SEC.
What is Dr. Kweli Thompson’s current role at Medtronic (MDT)?
Dr. Kweli Thompson currently serves as Senior Vice President and President, Cardiac Rhythm Management. He will transition from this role to lead Medtronic’s Neuroscience Portfolio as Executive Vice President and President.
What type of SEC filing did Medtronic (MDT) use to announce this change?
Medtronic used a Form 8-K to disclose this executive leadership change. Form 8-K is commonly used to report significant company events of interest to shareholders and the market.